JeraldPRadichMD

PubMed

• CML and the WHO: Why?
  Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya, Kebede Begna, Ravi Bhatia, Onyee Chan, Robert Collins, Peter Curtin, Daniel J DeAngelo, Mic...> ;Journal of Clinical Oncology. 2024 Mar 20
• 1 citations
  Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
  Winn, A., Deininger, M., Moore, J., Shah, N., Flynn, K., Atallah, E., Cortes, J., Kota, V., Larson, R., Mauro, M., Oehler, V., Pinilla-Ibarz, J., Radich, J., Thompson, J.> ;JAMA Network Open. 2023 Dec 1
• 1 citations
  A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
  Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich, Min Fang, David A Rizzieri, Guido Marcucci, Stephen A Strickland, Mark R Litz...> ;Leukemia. 2024 Jan 1
• 2 citations
  European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
  Nicholas C P Cross, Thomas Ernst, Susan Branford, Jean-Michel Cayuela, Michael Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Katerina Machova Polakova, Jerald P Rad...> ;Leukemia. 2023 Nov 1
• 1 citations
  Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
  David W Woolston, Nathan D Lee, Mazyar Shadman, Elena Latorre-Esteves, Xin Ray Tee, Jeanne Fredrickson, Brendan F Kohrn, Chaitra Ujjani, Ashley Eckel, Brian Till, Min ...> ;Haematologica. 2024 Mar 1
• 5 citations
  Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
  Laura W Dillon, Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H Smith, Elizabeth Schmidt, Charles C Valentine Iii, Jesse J Salk, Brent L Wood, Harry P Erb...> ;Haematologica. 2024 Feb 1
• The (near) miracle of therapy in chronic myeloid leukaemia.
  Jerald P Radich> ;British Journal of Haematology. 2023 Sep 1
• Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation.
  Sami B Kanaan, Francesca Urselli, Jerald P Radich, J Lee Nelson> ;Blood Advances. 2023 Oct 24
• 3 citations
  Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
  Sara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, Megan Othus, Zhuoxin Sun, Rhonda E Ries, Jim Wang, Amanda Leonti, Matthew A Kutny, Fabiana Ostronoff, Jerald P R...> ;Blood Advances. 2023 Oct 10
• 29 citations
  Management of chronic myeloid leukemia in 2023 - common ground and common sense.
  Jayastu Senapati, Koji Sasaki, Ghayas C Issa, Jeffrey H Lipton, Jerald P Radich, Elias Jabbour, Hagop M Kantarjian> ;Blood Cancer Journal. 2023 Apr 24
• Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.
  Christina M Termini, Anna Moseley, Megan Othus, Frederick R Appelbaum, Thomas R Chauncey, Harry P Erba, Min Fang, Stanley C Lee, Jasmine Naru, Era L Pogosova-Agadjanya...> ;Haematologica. 2023 Nov 1
• Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
  Laura W Dillon, Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H Smith, Elizabeth Schmidt, Charles C Valentine 3rd, Jesse J Salk, Brent L Wood, Harry P Erb...> ;Medrxiv. 2023 Mar 27
• 2 citations
  Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
  Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, Olga Sala-Torra, Philip A Stevenson, Christen H Martino, Yajuan J Liu, Min Fang, Mary-Elizabeth M Percival, An...> ;Leukemia & Lymphoma. 2023 May 1
• Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.
  Era L Pogosova-Agadjanyan, Xing Hua, Megan Othus, Frederick R Appelbaum, Thomas R Chauncey, Harry P Erba, Matthew P Fitzgibbon, Isaac C Jenkins, Min Fang, Stanley C Le...> ;Biomarker Research. 2023 Mar 16
• 1 citations
  CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries.
  Mika Matsuzaki, Alicia Annamalay, Pat Garcia-Gonzalez, Jerald Radich> ;Current Hematologic Malignancy Reports. 2023 Feb 1
• 2 citations
  Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
  Jerald P Radich, Matthew Wall, Susan Branford, Catarina D Campbell, Shalini Chaturvedi, Daniel J DeAngelo, Michael Deininger, Justin Guinney, Andreas Hochhaus, Timothy...> ;Haematologica. 2023 Jun 1
• 1 citations
  Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing.
  Olga Sala-Torra, Shishir Reddy, Ling-Hong Hung, Lan Beppu, David Wu, Jerald Radich, Ka Yee Yeung, Cecilia C S Yeung> ;PLOS Global Public Health. 2023 Jan 1
• 2 citations
  Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!
  Jerald Radich> ;American Journal of Hematology. 2023 Jan 1
• A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syn...
  Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L ...> ;Leukemia & Lymphoma. 2023 Feb 1
• 689 citations
  International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
  Daniel A Arber, Attilio Orazi, Robert P Hasserjian, Michael J Borowitz, Katherine R Calvo, Hans-Michael Kvasnicka, Sa A Wang, Adam Bagg, Tiziano Barbui, Susan Branford...> ;Blood. 2022 Sep 15
• 6 citations
  TTMV-RARA fusion as a recurrent cause of AML with APL characteristics.
  Olga Sala-Torra, Lan W Beppu, Faduma A Abukar, Jerald P Radich, Cecilia C S Yeung> ;Blood Advances. 2022 Jun 28
• 4 citations
  Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
  Kathryn E Flynn, Ehab Atallah, Li Lin, Neil P Shah, Richard T Silver, Richard A Larson, Javier Panilla-Ibarz, James E Thompson, Vivian G Oehler, Jerald P Radich, Vamsi...> ;Haematologica. 2022 Nov 1
• 3 citations
  AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.
  Deepti Reddi, Brandon W Seaton, David Woolston, Lauri Aicher, Luke D Monroe, Zhengwei J Mao, Jill C Harrell, Jerald P Radich, Anjali Advani, Nikolaos Papadantonakis, C...> ;Scientific Reports. 2022 Apr 6
• 6 citations
  Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice.
  Kristen Pettit, Alexandra Rezazadeh, Ehab L Atallah, Jerald Radich> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
• 1 citations
  Another Philadelphia story.
  Jerald P Radich> ;Haematologica. 2022 Mar 1
• Join now to see all

Journal Articles

• Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
  Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
• Philadelphia chromosome positive ALL.  
  Sala O, Radich JP, Hematological/Oncology Clinics of North America
• NCCN task force report: Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.  
  O’Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M, J Natl Compr Canc Netw 9:S1-25
• Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid.  
  Oehler V, Qin J, Ramakrishnan Facer RG, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich J, Leukemia 23:396-369
• Use if gene expression microarrays for the study of acute leukemia.  
  Bellido M, Stirewalt DL, Zhao LP, Radich JP, Expert Review of Molecular Diagnostics 6: 733-747
• Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells.  
  Stirewalt DL, Choi YE, Sharpless NE, Pogosova-Agadjanyan E, Cronk MR, Yukawa M, Larson EB, Wood BL, Appelbaum FR, Radich JP, Heimfeld S, Leukemia 23:391-393
• Early allogeneic transplantation for chronic myelogenous leukemia in the imatinib era: A preliminary assessment.  
  Radich J, Blood Cells, Molecules, & Diseases 37: 125-127
• The gamma catenin/CBP complex maintains surviving transcription in beta-catenin deficient/depleted cancer cells.  
  Kim YM, Ma H, Oehler VG, Gang EJ, Nguyen C, Masiello D, Liu H, Zhao Y, Radich J, Kahn M, Curr Cancer Drug Targets 11:213-225
• BCR-ABL-positive CML and BCR-ABL-negative myeloproliferative disorders – some common and some contrasting features.  
  Cross NCP, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM, Leukemia 22:1975-1985
• Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.  
  Radich JP, Cancer 118:300-311
• The detection and significance of minimal residual disease in acute and chronic leukemia.  
  Chung N-G, Buxhofer-Ausch V, Radich JP, Tissue Antigens 68: 371-375
• Practical guidelines for chronic myeloid leukemia response assessment.  
  Radich J, Clin Adv Hematology/Oncology
• Efficacy and safety of dasatinib in imatinib-resistant or –intolerant patients with chronic myeloid leukemia in blast phase.  
  Cortes J, Kim D-W, Raffoux E, Martinelli g, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang J-L, Hochhaus A, Khoury HJ, Brummerndort TH, Michalelet M, Rege-Cam..., Leukemia 22: 2176-2183
• Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP).  
  Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich JP, H..., Journal Clin Oncol 27:2404-4210
• Is transplantation for CML dead?  
  Radich JP, The Hematologist, Sept-Oct
• Lin 28 enhances tumorigenesis and is associated with advanced human malignancies.  
  Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng T, Toffanin S, O’Sulliavn M, Lu j, Philips LA Lockhar VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixe..., Nature Genetics, 41: 843-849
• The wasteland of relapsed adult ALL.  
  Radich JP, The Hematologist March-April
• Chronic Myeloid Leukemia. An Update of Concepts and Management Recommendations of European LeukemiaNet.  
  Baccarani, et al, J Clinical Oncol, 27:6041-6051
• Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses an have lower failure rates than thos...  
  White DL, Radich J, Soverini S, Saunder VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP, Haematologica 2012
• Downregulation of JunB expression in advanced phase chronic myeloid leukemia.  
  Hoshino K, Quintas-Cardama A, Radich JP, et al, Leuk Res 33:1361-1366
• High-dose imatinib in newly diagnosed chronic phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses.  
  Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J, J Clin Oncol 27: 4754-4759
• Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48 month follow-up results of a phase II study.  
  Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Dong-Wook K, Novick S, Gillis K..., Leukemia
• Solving the mysteries of myelodyplasia.  
  Radich JP, PLOS Medicine
• NCCN guidelines for chronic myelogenous leukemia.  
  O’Brien, et al, Journal of the NCCN, 7:984-1022
• Initial Molecular Response at 3 Months May Predict Both Responses and Event-free Survival at 24 Months in Imatinib-Resistant or Intolerant Patients With Philadelphia C...  
  Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MM, J Clin Oncol
• Join now to see all

Books/Book Chapters

• Molecular targets in AML 
  Chapter: Hematology 2001: American Society of Hematology Education Book 
  Page 68 - 73Radich JP
• Transplant approaches in CML 
  Chapter: Hematology 2002: American Society of Hematology Education Book 
  Page 124 - 130Radich JP

Abstracts/Posters

• Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
  Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation
  Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...
  Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex Sequencing
  Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia
  Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic graft-versus-host disease and other late complications of bone marrow transplantation 
  Seminars in Hemat. 28:250-259
• Bone marrow transplantation for chronic myelogenous leukemia (Review). 
  Seminars in Oncology 22:405-411
• Join now to see all